Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma [clinicaltrials:NCT00176280]

Bio2RDF uri

Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma [clinicaltrials:NCT00176280]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00176280

Bio2RDF identifier

NCT00176280

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00176280

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

-Overall study design: ...... 6, 7, 17, 18, 19, 20, and 21.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Randomized Phase 2 Trial of Pr ...... etastatic Renal Cell Carcinoma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:043280401d731050801d04ec6559768b]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:12de88a1251f1582891af74dd51ee1c1]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:da7631ba1b01ce8a9743777a6fdbdcf9]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:e35d04d2e7e4ad46c9dbdb86866c6abf]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:084968a1db42a042448cd2db0fcd80fb]

% of subjects with CR or PR evaluated after course 2 then every other course using RECIST for both cohorts [clinicaltrials_resource:6e0f1512bb4304eca79fd3ce826e1e7b]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Kentucky [clinicaltrials_resource:ab565984d309aebef94b58046b90d633]

condition [clinicaltrials_vocabulary:condition]

Renal Cell Carcinoma [clinicaltrials_resource:fd3bec4ec41be99313607e47079bc05d]

condition browse [clinicaltrials_vocabulary:condition-browse]

Carcinoma [clinicaltrials_resource:506566f9cdd0caf88175444976503e1f]

Carcinoma, Renal Cell [clinicaltrials_resource:fb995e7de226118d9ce83551673e6b7b]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Carcinoma [clinicaltrials_resource:506566f9cdd0caf88175444976503e1f]

Carcinoma, Renal Cell [clinicaltrials_resource:fb995e7de226118d9ce83551673e6b7b]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

STUDY SYNOPSIS O ...... d), days 1 and 7 of course 1.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00176280 [clinicaltrials_resource:f5042d7a9ed8e688cd179faf6805b44a]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Leukine [clinicaltrials_resource:4979d93e9077159c6af7bc48f7741033]

Dexamethasone [clinicaltrials_resource:6797a88b986f0aedad7d1a29454529fd]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Dexamethasone acetate [clinicaltrials_resource:3aceb7ffcdb81af25927c64a2943afbf]

Dexamethasone [clinicaltrials_resource:81150ffec96d15927ad7a74665708ef9]

BB 1101 [clinicaltrials_resource:9455fd6ce25c7014db1539bee52b8740]

Dexamethasone 21-phosphate [clinicaltrials_resource:9aea03ec731911e4ff43f23b2ed51296]

keyword [clinicaltrials_vocabulary:keyword]

5 FU

http://www.w3.org/2001/XMLSchema#string

5 Fluorouracil

http://www.w3.org/2001/XMLSchema#string

Carcinoma

http://www.w3.org/2001/XMLSchema#string

Dexamethasone

http://www.w3.org/2001/XMLSchema#string

Gemcitabine

http://www.w3.org/2001/XMLSchema#string

Leukine

http://www.w3.org/2001/XMLSchema#string

Metastatic

http://www.w3.org/2001/XMLSchema#string

RCC

http://www.w3.org/2001/XMLSchema#string

Renal Cell Carcinoma

http://www.w3.org/2001/XMLSchema#string

Renal

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Kentucky [clinicaltrials_resource:ab565984d309aebef94b58046b90d633]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00176280

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Randomized Phase II Trial of ...... tic Renal Cell Carcinoma (RCC)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

04-GU-51-B

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

John Rinehart, MD [clinicaltrials_resource:23714d36ef5a1a5add554e043a7b65a1]

overall status [clinicaltrials_vocabulary:overall-status]

Withdrawn [clinicaltrials_resource:f62dedad685b570f499b61e94084dab2]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

source [clinicaltrials_vocabulary:source]

University of Kentucky [clinicaltrials_resource:ab565984d309aebef94b58046b90d633]

start date [clinicaltrials_vocabulary:start-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00176280 study design [clinicaltrials_resource:bdc6f6ec21a97bcb928c8e183abf228b]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00176280

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

why stopped [clinicaltrials_vocabulary:why-stopped]

Slow accrual

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials:NCT00176280

http://www.w3.org/2001/XMLSchema#string

title

Randomized Phase 2 Trial of Pr ...... etastatic Renal Cell Carcinoma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Randomized Phase 2 Trial of Pr ...... a [clinicaltrials:NCT00176280]

@en